U.S. markets close in 2 hours 14 minutes
  • S&P 500

    3,782.18
    -13.36 (-0.35%)
     
  • Dow 30

    30,926.71
    -64.81 (-0.21%)
     
  • Nasdaq

    13,075.30
    -37.34 (-0.28%)
     
  • Russell 2000

    2,134.06
    -21.29 (-0.99%)
     
  • Crude Oil

    52.29
    -1.28 (-2.39%)
     
  • Gold

    1,828.90
    -22.50 (-1.22%)
     
  • Silver

    24.84
    -0.96 (-3.73%)
     
  • EUR/USD

    1.2086
    -0.0069 (-0.57%)
     
  • 10-Yr Bond

    1.0920
    -0.0370 (-3.28%)
     
  • GBP/USD

    1.3586
    -0.0105 (-0.77%)
     
  • USD/JPY

    103.8760
    +0.0600 (+0.06%)
     
  • BTC-USD

    35,343.53
    -2,495.11 (-6.59%)
     
  • CMC Crypto 200

    677.73
    -57.41 (-7.81%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.08 (-0.62%)
     

CytRx presents aldoxorubicin Phase 2b trial data

CytRx announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin has been selected for oral presentation at the 2014 American Society for Clinical Oncology Annual Meeting. Aldoxorubicin is currently being studied in a pivotal, global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. CytRx is also conducting two Phase 2 clinical trials evaluating aldoxorubicin in patients with late-stage glioblastoma and HIV-related Kaposi’s sarcoma.